INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Aga...

Glancy Binkow & Goldberg LLP reminds investors of Aeterna Zentaris Inc. (“Aeterna” or the “Company”) (NASDAQ:AEZS) that purchasers of Aeterna securities between October 18, 2012 and November 5, 2014, inclusive (the “Class Period”), have until January 12, 2015, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit filed in the United States District Court for the District of New Jersey.

Aeterna is a specialty biopharmaceutical company engaged in the development and commercialization of novel treatments in oncology and endocrinology. The Company is developing macimorelin − an orally active small molecule that stimulates the secretion of growth hormone − as a treatment for Adult Growth Hormone Deficiency. The Complaint alleges that defendants made false and/or misleading statements and failed to disclose material adverse facts about the Company’s business, operations and prospects. Specifically, defendants misrepresented or failed to disclose that: (1) the planned analysis of macimorelin’s pivotal clinical trial failed to meet its primary efficacy endpoint pursuant to the Special Protocol Assessment agreement letter between the Company and the FDA; (2) insufficient data existed to confirm that the patients in the clinical trial were accurately diagnosed with Adult Growth Hormone Deficiency; (3) a serious cardiac event could have been attributed to macimorelin; (4) as a result, the FDA would not approve the New Drug Application for macimorelin in its present form; and (5), the Company’s statements about its business, operations and prospects, including statements about macimorelin’s prospects for FDA approval, were materially false and misleading and/or lacked a reasonable basis.

On November 6, 2014, the Company revealed that the FDA determined that the New Drug Application for macimorelin could not be approved in its present form. The FDA concluded that the planned analysis of the Company’s pivotal trial did not meet its stated primary efficacy objective, and “in light of the failed primary analysis and data deficiencies noted, the clinical trial does not by itself support the indication.” In addition, the FDA noted that a serious event of electrocardiogram QT interval prolongation occurred for which attribution to the drug could not be excluded, and a dedicated QT interval study would be necessary. Following this news, Aeterna shares declined nearly 50%, or $0.64 per share, to close on November 6, 2014, at $0.65 per share, on unusually heavy volume.

If you are a member of the Class described above, you may move the Court no later than January 12, 2015, to serve as lead plaintiff; however, you must meet certain legal requirements. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Casey Sadler, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, at [phone], by e-mail to [e-mail], or visit our website at http://www.glancylaw.com. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Binkow & Goldberg LLP, Los Angeles, CACasey Sadler(310) 201-9150(888) [e-mail]